On Tuesday, Evolus Inc (NASDAQ: EOLS) opened lower -7.13% from the last session, before settling in for the closing price of $9.96. Price fluctuations for EOLS have ranged from $8.67 to $17.82 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 50.12%. Company’s average yearly earnings per share was noted 23.26% at the time writing. With a float of $56.90 million, this company’s outstanding shares have now reached $64.45 million.
Let’s determine the extent of company efficiency that accounts for 332 employees. In terms of profitability, gross margin is 67.73%, operating margin of -14.2%, and the pretax margin is -20.19%.
Evolus Inc (EOLS) Insider Activity
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Evolus Inc is 11.75%, while institutional ownership is 84.37%. The most recent insider transaction that took place on Jun 13 ’25, was worth 1,119,141. In this transaction an insider of this company sold 111,323 shares at a rate of $10.05, taking the stock ownership to the 381,509 shares. Before that another transaction happened on Jun 16 ’25, when Company’s insider sold 16,582 for $9.89, making the entire transaction worth $164,054. This insider now owns 364,927 shares in total.
Evolus Inc (EOLS) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 23.26% per share during the next fiscal year.
Evolus Inc (NASDAQ: EOLS) Trading Performance Indicators
Check out the current performance indicators for Evolus Inc (EOLS). In the past quarter, the stock posted a quick ratio of 2.16. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.17.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.89, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach 0.57 in one year’s time.
Technical Analysis of Evolus Inc (EOLS)
Looking closely at Evolus Inc (NASDAQ: EOLS), its last 5-days average volume was 1.37 million, which is a jump from its year-to-date volume of 0.96 million. As of the previous 9 days, the stock’s Stochastic %D was 34.35%. Additionally, its Average True Range was 0.55.
During the past 100 days, Evolus Inc’s (EOLS) raw stochastic average was set at 6.86%, which indicates a significant decrease from 15.43% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.44% in the past 14 days, which was lower than the 61.28% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.27, while its 200-day Moving Average is $12.98. However, in the short run, Evolus Inc’s stock first resistance to watch stands at $9.73. Second resistance stands at $10.20. The third major resistance level sits at $10.53. If the price goes on to break the first support level at $8.93, it is likely to go to the next support level at $8.60. Should the price break the second support level, the third support level stands at $8.13.
Evolus Inc (NASDAQ: EOLS) Key Stats
There are currently 64,476K shares outstanding in the company with a market cap of 596.40 million. Presently, the company’s annual sales total 266,270 K according to its annual income of -50,420 K. Last quarter, the company’s sales amounted to 68,520 K and its income totaled -18,890 K.
